P1.13-41 in Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers With MET Mutations Including Exon 14 Skipping

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.898
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P3.09-18 Identification of MET Exon 14 Skipping Mutations by FusionPlexTM Solid Tumor Panel

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Brief Report: DNA-based Versus RNA-based Detection of MET Exon 14 Skipping Events in Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

P1.01-74 MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy